Rogel Cancer Center: University of Michigan
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00724568
- Locations
- 🇺🇸
Dana Farber Cancer Institute (and Massachusetts General), Boston, Massachusetts, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00645333
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 89
- Registration Number
- NCT00645593
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University, Stanford, California, United States
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00644696
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Procedure: diffusion MRI
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00645359
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant
- Conditions
- Graft Versus Host Disease
- Interventions
- Procedure: stem cell transplant
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00639717
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- Conditions
- Fallopian Tube CancerPeritoneal CancerOvarian Cancer
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00637390
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00623935
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00616109
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
- Conditions
- Multiple MyelomaPlasma Cell Leukemia
- Interventions
- Drug: Fludarabine/Busulfan x 4 daysProcedure: stem cell transplant
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00615589
- Locations
- 🇺🇸
University of Michigan,Department of Internal Med. Hematology- Oncology, Ann Arbor, Michigan, United States